The Cigna Group Reports Strong Third Quarter 2026 Performance, Driven by Revenue Growth and Strategic Business Execution
The Cigna Group, a global health services company, has announced its financial results for the third quarter of 2026, reporting solid business performance, increased total revenues and continued progress across its healthcare and pharmacy services operations. The company’s latest financial results reflect disciplined execution of its business strategy, continued investment in customer-focused healthcare solutions and efforts to improve affordability and accessibility across an increasingly complex healthcare environment.
The third-quarter performance demonstrates the company’s ability to maintain momentum across its major business segments, particularly Evernorth Health Services and Cigna Healthcare. Both businesses contributed to overall revenue growth, while strategic investments, operational improvements and cost-management initiatives continued to support the company’s long-term financial objectives.
Alongside its quarterly financial announcement, The Cigna Group highlighted its commitment to advancing a sustainable growth strategy focused on delivering greater value to customers, improving personalized healthcare experiences and strengthening its operational capabilities. The company also raised its financial outlook for 2026, reflecting confidence in its business performance and its ability to execute its strategic priorities.
Brian Evanko, President and Chief Executive Officer of The Cigna Group, emphasized the importance of the company’s next phase of profitable growth and its focus on improving healthcare experiences.
“Our vision for The Cigna Group’s next chapter of profitable growth is grounded in delivering greater value and personalized experiences for our customers, with three priorities: driving core growth, leveraging our distinct capabilities, and executing with discipline,” said Brian Evanko.
He further explained that the company’s third-quarter results demonstrate the progress being made through its strategic initiatives. These efforts are intended to make healthcare more affordable and personalized while advancing the company’s Accelerate to One program. The initiative focuses on improving productivity, reducing operating costs and supporting sustainable earnings growth over the long term.
The Cigna Group Reports Third Quarter Financial Performance
For the third quarter of 2026, The Cigna Group reported shareholders’ net income of $1.4 billion, equivalent to $5.47 per share. This compares with shareholders’ net income of $1.9 billion, or $6.98 per share, reported during the third quarter of 2025.
The year-over-year decline in shareholders’ net income primarily reflected the absence of an after-tax gain on sale that had been recognized in the corresponding quarter of the previous year. Consequently, the difference in reported net income does not solely reflect changes in the company’s underlying operating performance.
Adjusted income from operations for the third quarter of 2026 reached $2.1 billion, or $7.98 per share. This compares with adjusted income from operations of approximately $2.1 billion, or $7.83 per share, during the third quarter of 2025.
The adjusted earnings results demonstrate the company’s ability to maintain operating performance while navigating changing business conditions, customer membership trends and strategic investments across its healthcare services portfolio.
The Cigna Group uses adjusted income from operations as an important measure of its underlying business performance. This financial metric provides investors with additional insight into operating results by excluding certain items that may not reflect ongoing business activities.
The company also provided a reconciliation of shareholders’ net income to adjusted income from operations in its earnings release, offering additional transparency into the differences between reported and adjusted financial results.
Total Revenue Increases 6% Across Major Business Segments
One of the key highlights of The Cigna Group’s third-quarter 2026 performance was its continued revenue growth. Total revenues increased 6% compared with the third quarter of 2025, supported by contributions from both Evernorth Health Services and Cigna Healthcare.
The growth reflects demand across the company’s healthcare services portfolio and the continued importance of its pharmacy, specialty care and medical insurance operations.
Evernorth Health Services remains an important contributor to the company’s overall business performance, providing pharmacy benefit management, specialty pharmacy, healthcare services and related solutions. Meanwhile, Cigna Healthcare continues to support customers through its health insurance and medical benefits offerings.
Although total revenue increased, adjusted income from operations remained relatively stable compared with the previous year. Strong growth in Cigna Healthcare and Specialty and Care Services helped offset lower contributions from Pharmacy Benefit Services.
This performance highlights the different operating conditions affecting the company’s business segments and the importance of maintaining a diversified healthcare services portfolio.
Operating Expenses and Financial Position
The Cigna Group continued to manage its operating expenses while investing in initiatives designed to support future business growth.
The company’s selling, general and administrative (SG&A) expense ratio was 4.9% in the third quarter of 2026, compared with 4.8% during the same period in 2025.
Meanwhile, the adjusted SG&A expense ratio increased to 4.7%, compared with 4.6% in the third quarter of the previous year.
The slight increases in both expense ratios primarily reflected investments and initiatives intended to strengthen the company’s long-term growth capabilities. These investments were partially offset by operational efficiencies achieved across its businesses.
The company continues to focus on improving productivity, streamlining operations and identifying opportunities to reduce unnecessary costs. Its Accelerate to One initiative is an important part of these efforts, supporting a more efficient operating structure while helping the company maintain the quality and value of its healthcare services.
The Cigna Group also reported an improvement in its debt-to-capitalization ratio. As of September 30, 2026, the ratio stood at 41.8%, compared with 44.9% on September 30, 2025, and 43.0% as of December 31, 2025.
The reduction indicates an improved capital structure compared with the corresponding reporting periods and reflects the company’s ongoing financial management priorities.
Share Repurchases Demonstrate Commitment to Shareholder Value
The company continued its capital allocation activities through the repurchase of its common stock.
Year to date through November 4, 2026, The Cigna Group repurchased approximately 1.8 million shares of common stock for a total investment of approximately $500 million.
Share repurchases form part of the company’s broader capital allocation strategy, which seeks to balance investments in business operations, financial flexibility and returns to shareholders.
By maintaining a disciplined approach to capital allocation, the company aims to support its long-term financial objectives while continuing to invest in healthcare capabilities, technology and operational improvements.
Customer Relationships and Membership Trends
As of September 30, 2026, The Cigna Group reported total customer relationships of 177.6 million, representing a 6% decrease compared with December 31, 2025.
The reduction was primarily attributable to lower pharmacy and behavioral customer numbers. The company noted that these changes reflected expected client transitions and the termination of a government contract.
Total pharmacy customers decreased 5% from December 31, 2025, reaching 117.7 million as of September 30, 2026.
The decline reflected anticipated client transitions and lower membership associated with health plan clients. These changes are part of the evolving customer and membership environment within the pharmacy services business.
Behavioral health customers decreased 19% over the same period to approximately 23 million.
This reduction was primarily related to the termination of a government contract. However, the company indicated that the contract termination had a minimal impact on its overall revenues and adjusted income from operations.
Despite the reductions in pharmacy and behavioral customer relationships, medical customer membership showed positive momentum.
Total medical customers increased 2% from December 31, 2025, reaching 18.5 million as of September 30, 2026.
The increase reflected membership growth in the company’s Middle and Select markets, partially offset by lower membership in National Accounts.
These customer trends demonstrate the varying performance across The Cigna Group’s business categories. While certain customer segments experienced declines, growth in medical membership highlights continued opportunities within the company’s healthcare coverage operations.
Evernorth Health Services Maintains Revenue Growth
Evernorth Health Services continued to contribute significantly to The Cigna Group’s third-quarter financial performance.
During the third quarter of 2026, Evernorth Health Services reported a 6% increase in adjusted revenues compared with the third quarter of 2025.
However, adjusted income from operations before taxes decreased 4% year over year.
The overall performance reflected differences between the company’s pharmacy benefit management operations and its specialty and care services businesses.
Evernorth operates across several healthcare service categories, including pharmacy benefit management, specialty pharmacy distribution and care-related services. Its business model focuses on supporting customers, employers, health plans and healthcare providers through solutions designed to improve healthcare access, affordability and coordination.
Pharmacy Benefit Services Performance
Within Evernorth Health Services, Pharmacy Benefit Services recorded a 9% increase in adjusted revenues during the third quarter of 2026 compared with the same quarter in 2025.
The revenue increase was primarily driven by changes in drug mix, reflecting the composition of medications distributed and managed through the company’s pharmacy benefit operations.
Despite the revenue growth, adjusted income from operations before taxes declined 22% year over year.
The decrease primarily reflected the impact of large client contract renewals and strategic investments. These developments were consistent with the company’s previous commentary regarding the operating environment and financial expectations for its pharmacy benefit business.
Contract renewals can influence the financial performance of pharmacy benefit management operations because negotiated pricing, service arrangements and customer requirements may affect operating margins.
The company continues to focus on maintaining its competitive position while investing in capabilities that support customers and healthcare partners.
Although Pharmacy Benefit Services experienced lower operating income, its revenue growth demonstrates continued business activity and the importance of pharmacy-related services within Evernorth’s overall portfolio.
Specialty and Care Services Delivers Strong Operating Growth
Specialty and Care Services also contributed to Evernorth Health Services’ performance, reporting a 1% increase in adjusted revenues during the third quarter of 2026 compared with the previous year.
Revenue growth was supported by strong specialty distribution performance. However, this increase was partially offset by lower specialty pharmacy revenues.
The decline in specialty pharmacy revenue was primarily associated with greater adoption of biosimilars and specialty generic medications.
Biosimilars are biological products that are highly similar to already approved reference biologic medicines, while specialty generics provide lower-cost alternatives to certain specialty medications.
Greater adoption of these treatments can help reduce medication expenses for customers and patients while supporting broader efforts to improve healthcare affordability.
Although the increased adoption of biosimilars and specialty generics affected certain revenue categories, it also contributed positively to Specialty and Care Services’ operating performance.
Adjusted income from operations before taxes increased 15% during the third quarter of 2026 compared with the third quarter of 2025.
The improvement primarily reflected strong organic growth across specialty businesses, including the increased adoption of biosimilars and specialty generic medications.
This performance highlights the company’s ability to generate operating growth through specialty healthcare services while supporting efforts to make treatment more affordable.
Cigna Healthcare Supports Overall Business Growth
Cigna Healthcare was another important contributor to The Cigna Group’s third-quarter performance.
Alongside Specialty and Care Services, the business helped offset lower operating contributions from Pharmacy Benefit Services, supporting stable adjusted income from operations across the company.
Medical customer membership increased 2% compared with December 31, 2025, reaching 18.5 million at the end of September 2026.
Growth in Middle and Select markets contributed to the increase, although lower membership in National Accounts partially offset the gains.
The company continues to focus on providing healthcare coverage and services that address the needs of individuals, employers and other customers.
By combining healthcare coverage capabilities with Evernorth’s pharmacy and specialty services, The Cigna Group aims to create a more integrated healthcare experience that supports affordability, accessibility and personalized care.
Accelerate to One Strategy Focuses on Productivity and Efficiency
An important part of The Cigna Group’s future growth strategy is its Accelerate to One initiative.
The program is designed to improve organizational productivity, reduce operating costs and strengthen the company’s ability to deliver sustainable financial results.
The initiative supports the company’s broader objective of creating a more efficient operating model while maintaining investments in healthcare capabilities and customer experiences.
Management believes that disciplined execution, operational simplification and improved productivity will be important factors in achieving long-term earnings growth.
The company is also prioritizing investments in its core businesses and leveraging its existing capabilities to address increasingly complex healthcare needs.
These priorities are intended to strengthen its competitive position while supporting better value for customers and healthcare partners.
The Cigna Group Raises Its 2026 Financial Outlook
Following its third-quarter performance, The Cigna Group raised its financial outlook for 2026, signaling management’s confidence in the company’s business strategy and future operating performance.
The updated outlook reflects the company’s continued focus on revenue growth, operational discipline, customer value and long-term earnings expansion.
The company expects its major business segments to remain important contributors to its overall financial performance as it continues executing its strategic priorities.
Its investments in specialty healthcare, pharmacy services, customer experience improvements and operational efficiency are expected to support its longer-term growth objectives.
The decision to raise the 2026 outlook also reinforces the company’s emphasis on disciplined financial management and its ability to navigate changing healthcare market conditions.
The Cigna Group’s third-quarter 2026 results demonstrate continued revenue growth and stable adjusted operating income, supported by strong contributions from Cigna Healthcare and Specialty and Care Services.
While lower contributions from Pharmacy Benefit Services and declining pharmacy and behavioral customer relationships remain important business considerations, the company continues to focus on strengthening its operations and improving customer value.
The increased adoption of biosimilars and specialty generics also highlights the changing dynamics of the pharmaceutical market and the opportunities available to healthcare companies that can support more affordable treatment options.
Moving forward, The Cigna Group plans to concentrate on three major priorities: driving core business growth, leveraging its distinct healthcare capabilities and maintaining disciplined execution.
Through these initiatives, the company aims to improve healthcare affordability, deliver more personalized customer experiences, enhance operational productivity and support sustainable earnings growth.
With its raised 2026 financial outlook, continued investments in healthcare services and focus on operational efficiency, The Cigna Group is positioning itself to strengthen its business performance and advance its long-term growth strategy.
Source link: https://newsroom.thecignagroup.com/
